NCT00154986

Brief Summary

An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities were selected from transwell invasion chambers.Using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified IGFBP-3 as an invasion-suppressor gene. We plan to study the role of IGFBP-3 in ovarian cancer invasion.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2004

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2004

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2005

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 9, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 12, 2005

Completed
Last Updated

September 12, 2005

Status Verified

April 1, 2004

First QC Date

September 9, 2005

Last Update Submit

September 9, 2005

Conditions

Ovarian Carcinoma

Keywords

invasionmigrationmetastasisIGFBP-3transfectionsignal transduction.

Outcome Measures

Primary Outcomes (1)

  • migration, invasion, metastasis

Secondary Outcomes (1)

  • transfection efficiency

Interventions

immunohistochemical staining, transfection, invasion assayPROCEDURE

Eligibility Criteria

Age21 Years - 80 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ovarian Endometrioid Adenocarcinoma

You may not qualify if:

  • Other types of ovaria epithelial cell carcinoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwna University Hospital

Taipei, 10020, Taiwan

RECRUITING

MeSH Terms

Conditions

Ovarian NeoplasmsNeoplasm Metastasis

Interventions

Transfection

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal DisordersNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Gene Transfer TechniquesGenetic TechniquesInvestigative TechniquesRecombination, GeneticGenetic Phenomena

Study Officials

  • Torng Pao-Ling, MD, PhD

    Department of Obsteteric and Gynecology, National Tiawan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Torng Pao-Ling, MD, PhD

CONTACT

886223123456pltorng@ha.mc.ntu.edu.tw

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 9, 2005

First Posted

September 12, 2005

Study Start

August 1, 2004

Study Completion

July 1, 2005

Last Updated

September 12, 2005

Record last verified: 2004-04

Locations

TW(1)